Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells

Clinical Cancer Research

Volumn 15, Issue 21, 2009, Pages 6519-6528

  Warner, Steven L ^a   Stephens, Bret J ^a   Nwokenkwo, Stanley ^a   Hostetter, Galen ^a   Sugeng, Anastasia ^a   Hidalgo, Manuel ^b   Trent, Jeffery M ^a   Han, Haiyong ^a   Von Hoff, Daniel D ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; PACLITAXEL; PROTEIN TPX2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; CARCINOGENICITY; CELL IMMORTALIZATION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; TISSUE CULTURE; TISSUE MICROARRAY; TUMOR XENOGRAFT; UPREGULATION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GENE DOSAGE; HUMANS; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; NUCLEAR PROTEINS; PACLITAXEL; PANCREATIC NEOPLASMS; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 70350743121     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0077     Document Type: Article

References (26)

1. Jemal A, Siegel R, WardE, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Nowak NJ, Gaile D, Conroy JM, et al. Genomewide aberrations in pancreatic adenocarcinoma. Cancer Genet Cytogenet 2005;161:36-50.
3. Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A. AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene 2006;25:4831-4839 (Pubitemid 44201174)
4. Harada T, Baril P, Gangeswaran R, et al. Identification of genetic alterations in pancreatic cancer by the combineduse of tissue microdissection and array-based comparative genomic hybridisation. Br J Cancer 2007;96: 373-382 (Pubitemid 46160645)
5. Harada T, Chelala C, Bhakta V, et al. Genomewide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 2007.
6. Fukushige S, Waldman FM, Kimura M, et al. Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 1997; 19:161-169 (Pubitemid 27278803)
7. Aguirre AJ, Brennan C, Bailey G, et al. Highresolution characterization of the pancreatic adenocarcinoma genome. Proc Natl AcadSci U S A 2004;101:9067-9072 (Pubitemid 38781612)
8. Tonon G, Wong KK, Maulik G, et al. Highresolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 2005; 102:9625-9630 (Pubitemid 40981731)
9. Lin DM, Ma Y, Xiao T, et al. [TPX2 expression andits significance in squamous cell carcinoma of lung]. Zhonghua Bing Li Xue Za Zhi 2006;35: 540-544
10. Smith LT, Mayerson J, Nowak NJ, et al. 20q11.1 amplification in giant-cell tumor of bone: array CGH, FISH, and association with outcome. Genes Chromosomes Cancer 2006; 45:957-966
11. Gruss OJ, Vernos I. The mechanism of spindle assembly: functions of Ran andits target TPX2. J Cell Biol 2004;166:949-955 (Pubitemid 39304757)
12. Gruss OJ, Carazo-Salas RE, Schatz CA, et al. Ran induces spindle assembly by reversing the inhibitory effect of importin α on TPX2 activity. Cell 2001;104:83-93.
13. Kufer TA, Sillje HH, Korner R, Gruss OJ, Meraldi P, Nigg EA. Human TPX2 is required for targeting Aurora-A kinase to the spindle. J Cell Biol 2002;158:617-623 (Pubitemid 34920101)
14. Bayliss R, Sardon T, Ebert J, Lindner D, Vernos I, Conti E. Determinants for Aurora-A activation andAuro ra-B discrimination by TPX2. Cell Cycle 2004;3:404-407 (Pubitemid 40278221)
15. Ouyang H, Mou L, Luk C, et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype andphenotype. Am J Pathol 2000;157:1623-1631 (Pubitemid 30943220)
16. Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: pitfalls andpotential. Biotechniques 1999;26:112-22, 24-25
17. Gray PJ, Jr., Bearss DJ, Han H, et al. Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 2004;3:641-646 (Pubitemid 39193743)
18. Krishan A. Rapidflow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 1975;66:188-193
19. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652-4661 (Pubitemid 44297818)
20. Hata T, Furukawa T, Sunamura M, et al. RNA interference targeting aurora kinase a suppresses tumor growth andenhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005;65:2899-2905 (Pubitemid 40490094)
21. Scharer CD, Laycock N, Osunkoya AO, et al. Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med2008;6:79.
22. Yang H, He L, Kruk P, Nicosia SV, Cheng JQ. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53- dependent manner in ovarian cancer cells. Int J Cancer 2006;119:2304-2312 (Pubitemid 44546949)
23. Morgan-Lappe SE, Tucker LA, Huang X, et al. Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, andst earoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res 2007;67:4390-4398 (Pubitemid 46815088)
24. Jackson AL, Mao M, Kobayashi S, et al. Chromosome 20q amplification regulates in vitro response to Kinesin-5 inhibitor. Cancer Inform 2008;6:147-164
25. Eyers PA, Erikson E, Chen LG, Maller JL. A novel mechanism for activation of the protein kinase Aurora A. Curr Biol 2003;13:691-697 (Pubitemid 36453320)
26. Anderson K, Yang J, Koretke K, et al. Binding of TPX2 to Aurora A alters substrate and inhibitor interactions. Biochemistry 2007;46: 10287-10295 (Pubitemid 350067622)